FTSE 100

Key insight

AstraZeneca's 6%+ plunge on BMS merger rumours and a 6.4% crash in oil dragging Shell and BP are masking broader index resilience — the FTSE's flat print today significantly understates underlying sector rotation strength.

The FTSE 100 is drifting just below the 10,900 all-time high resistance zone, caught between a sharp energy/pharma selloff and rate-cut tailwinds supporting domestically-focused housebuilders.

Main risk

AstraZeneca–Bristol Myers Squibb Merger Speculation

AstraZeneca is the FTSE 100's largest constituent by weight; a sustained 6%+ single-day decline creates meaningful index-level drag, and any deal uncertainty could keep the stock depressed for weeks near the 11,000 resistance ceiling.